Лерканидипин – дигидропиридин III поколения сверхдлительного действия

1. Дедова И.С., Преображенский Д.В., Сидоренко Б.А., Тарыкина Е.В. и др. Лерканидипин – новый антагонист кальция третьего поколения: клиническая фармакология и опыт применения при лечении артериальной гипертензии. Рус. мед. журн. 2006; 20: 1411–7.
2. Одуд А.М, Прихода И.В. Эффективность применения лерканидипина у больных с изолированной систолической гипертензией. http://rql.net.ua/cardio_j/2006/1/odud.htm
3. Acanfora D, Trojano L, Gheorghiade M et al. A randomized, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina: effects on myocardial ischemia and heart rate variability. Am J Ther 2002; 9 (5): S 444–53.
4. Bang LM, Chapman TM, Goa KL (New Zealand). Лерканидипин: обзор эффективности в терапии артериальной терапии. Drugs 2003; 63 (22): 2449–72.
5. Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): S375–9.
6. Barbagallo Sangiorgi G, Putignano E, Calcara L et al. Efficacy and tolerability of lercanidipine vs. captopril in patients with mild to moderate hypertension in a double-blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S36–9.
7. Barchielli M, Dolfini E, Farina P et al. Clinical pharmacokinetics of lercanidipine. J Cardiovasc. Pharmacol 1997; 29 (Suppl. 2): S1–S15.
8. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. 
The ELYPSE study. Blood Press 2002; 11 (2): S95–100.
9. Borghi С, Prandin MG, Dormi A et al. The use of lercanidipine can improve the individual tolerability in dihydropyridine calcium blockers in hypertensive patients. J Hypertens 2000; 18 (Suppl. 2): S155–6 (abstract).
10. Cargnoni A, Benigno M, Ferrari F et al. Effects of lercanidipine and its enantiomers on ischemia and repefusion-1. J Cardiovasc Pharmacol 1997; 29 (Suppl. 1): S48–S62.
11. Cavallini A, Terzi G. Effects of antihypertensive therapy with lercanidipine and verapamil on cardiac electrical activity in patients with hypertension: a randomized, double-blind pilot study. Curr Ther Res 2000; 61 (7): S 477–87.
12. Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercanidipine, lacidipine and nifidepine GITS on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 3: S 203–12.
13. Dalla Vestra M, Pozza G, Mosca A, GrazioliI V et al. Влияние лерканидипина на уровень экскреции альбумина у гипертензивных больных СД типа 2 в сравнении с рамиприлом. Медицина неотложных состояний. 2006; 2(3).
14. Fogari R, Malamani GD, Zoppi A et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel group study. Curr Ther Res Clin Exp 2000; 61: S 850–62.
15. Fogari R, Mugellini A, Corradi L et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract no. P1.191]. J Hypertens 2000; 18 (Suppl. 2): S65.
16. Herbette LG, Vecchiarelli M, Leonardi A. Lercanidipine: Short plasma half-life, long duration of action. J Cardiovasc Pharmacol 1997; 29 (Suppl. 1): S19–S24.
17. Herrera J, Ghais Z, Gonzalez L. Antihypertensive treatment with a calcium channel blocker in postmenopausal women: prospective study in a primary health care setting [abstract no. P0680]. J Hypertens 2002; 20 (Suppl. 4): S162.
18. James IGV, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002; 16 (8): S605–10.
19. Leonetti G, Magnani B, Pessina AC et al. Tolerability of longterm treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15 (11): S932–40.
20. Licher ThF, Cosebtino F. The classification of calcium antagonists and their selection in the treatment of hypertension. Drugs 1998; 55 (4): S309–17.
21. Macchiarulo C, Pieri R, Mitolo DC et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res 2001; 62 (4): S236–53.
22. McClellan KJ, Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000; 60 (5): 1123–40.
23. Meredith PA. Duration of action and through to peak rations of calcium antagonists. – Research Clin Forums 1994; 16 (1): S29–41.
24. Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double blind controlled study. J Cardiovasc Pharmacol1997; 29 (Suppl. 2): S26–30.
25. Nayler WG. Amlodipine. Berlin, 1995: 1–273.
26. Notarbartolo A, Rengo F, Scafidi V et al. Long-term effects of lercanidipine on the lipoprotein and aholipoprotein profile of patients with mild to moderate essential hypertension Curr Ther Res 1999; 60 (4): S228–36.
27. Paterna S, Licata A, Arnone S et al. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S50–3.
28. Pedrinelli R, Dell’Omo G, Nuti M et al. Heterogenous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens 2003; 21: S1969–73.
29. Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S31–5.
30. Rengo F, Romis L. Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of resistant essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S54–8.
31. Romito R, Pansini MI, Perticone F et al. Comparative effect of lercanidipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercandipine in Adults (LEAD) study. J Clin Hypertens 2003; 5 (4): S249–53.
32. Rossoni G, Bernareggi M, De Gennaro Colonna V et al. Lercanidipine protects the heart from low-flow ischemia damage and antagonizes the vasopressor activity of endothelin-1. J Cardiovascul Pharmacol1997; 29 (Suppl. 1): S41–7.
33. S’anchez A, Sayans R, Alvarez JL et al. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril [abstract №12]. Fourth European Meeting on Calcium Antagonists 1999. Amsterdam.
34. Testa R, Leonardi A, Tajana A et al. Lercanidipine (Rec 15/2375): a novel 1,4-dihydropyridine calcium antagonist for hypertension. Cardiovasc Drug Reviews 1997; 15 (3): S187–219].
35. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Pressure 1996; 5: S206–8.
36. Triggle DJ. Mechanisms of action of calcium channel antagonists. In: Calcium antagonists in clinical medicine. Ed. by M.Epstein. Philadelphia, 1998: 1–26.
37. Van Zweiten PA, Pfaffendorf M. Pharmacology of dihydropyridine calcium antagonists. Relatiomship between lipophilicity and pharmacodynamic response J Hypertens 1993; 11 (Suppl. 6): S3–11.

Т.Е.Морозова, О.А.Вартанова 

Кафедра клинической фармакологии и фармакотерапии ФППОВ ГОУ ВПО Первый МГМУ им. И.М.Сеченова